{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:10:19Z","timestamp":1772752219593,"version":"3.50.1"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI19C0811"],"award-info":[{"award-number":["HI19C0811"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The effect of renin-angiotensin-aldosterone system (RAAS) inhibitors in coronavirus disease 19 (Covid-19) patients has not been fully investigated. We evaluated the association between RAAS inhibitor use and outcomes of Covid-19.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This study was a retrospective observational cohort study that used data based on insurance benefit claims sent to the Health Insurance Review and Assessment Service of Korea by May 15, 2020. These claims comprised all Covid-19 tested cases and the history of medical service use in these patients for the past five years. The primary outcome was all-cause mortality, and the rate of ventilator care was compared between the groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>From a total of 7,590 patients diagnosed with Covid-19, two distinct cohorts were generated based on RAAS inhibitors prescribed within 6 months before Covid-19 diagnosis. A total of 1,111 patients was prescribed RAAS inhibitors, and 794 patients were prescribed antihypertensive drugs, excluding RAAS inhibitors. In propensity-score matched analysis, 666 pairs of data set were generated, and all-cause mortality of the RAAS inhibitor group showed no significant difference compared with the non-RAAS inhibitor group (14.6% vs. 11.1%; hazard ratio [HR], 0.79; 95% confidence interval [CI], 0.54\u20131.15; p = 0.22). The rate of ventilator care was not significantly different between the two groups (4.4% vs. 4.1%; HR, 1.04; 95%CI, 0.60\u20131.79; p = 0.89).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>RAAS inhibitor treatment did not appear to increase the mortality of Covid-19 patients compared with other antihypertensive drugs, suggesting that they may be safely continued in Covid-19 patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0248058","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T18:43:09Z","timestamp":1615488189000},"page":"e0248058","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of renin-angiotensin-aldosterone system inhibitors on Covid-19 patients in Korea"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7794-3547","authenticated-orcid":true,"given":"Jungchan","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5508-7519","authenticated-orcid":true,"given":"Seung-Hwa","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seng Chan","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinseob","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwangmo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"pone.0248058.ref001","unstructured":"World Health Organization. Rolling updates on coronavirus disease (COVID-19) [Internet]. 2020 [cited 2020 Mar 31]. Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/events-as-they-happen."},{"key":"pone.0248058.ref002","unstructured":"The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team China CDC. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronaviurs Diseases. Vital Surveillances. 2020."},{"key":"pone.0248058.ref003","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19","volume":"382","author":"M Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0248058.ref004","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ddr.21656","article-title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics","volume":"81","author":"D Gurwitz","year":"2020","journal-title":"Drug Dev Res"},{"key":"pone.0248058.ref005","first-page":"125","article-title":"Role of the vasodilator peptide angiotensin-(1\u20137) in cardiovascular drug therapy","volume":"3","author":"C Schindler","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"pone.0248058.ref006","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Y Imai","year":"2005","journal-title":"Nature"},{"key":"pone.0248058.ref007","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/HYPERTENSIONAHA.120.15082","article-title":"Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers","volume":"75","author":"AHJ Danser","year":"2020","journal-title":"Hypertension"},{"key":"pone.0248058.ref008","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/eurheartj\/ehaa235","article-title":"SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?","volume":"41","author":"GM Kuster","year":"2020","journal-title":"Eur Heart J"},{"key":"pone.0248058.ref009","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamacardio.2020.1282","article-title":"Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers","volume":"5","author":"C Bavishi","year":"2020","journal-title":"JAMA Cardiol"},{"key":"pone.0248058.ref010","unstructured":"ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic [Internet]. 2020 [cited 2020 Mar 31]. Available from: https:\/\/www.escardio.org\/Education\/COVID-19-and-Cardiology\/ESC-COVID-19-Guidance."},{"key":"pone.0248058.ref011","first-page":"467","article-title":"Conversion of National Health Insurance Service-National Sample Cohort (NHIS-NSC) Database into Observational Medical Outcomes Partnership-Common Data Model (OMOP-CDM)","volume":"245","author":"SC You","year":"2017","journal-title":"Stud Health Technol Inform"},{"key":"pone.0248058.ref012","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/amiajnl-2011-000376","article-title":"Validation of a common data model for active safety surveillance research","volume":"19","author":"JM Overhage","year":"2012","journal-title":"J Am Med Inform Assoc"},{"key":"pone.0248058.ref013","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMoa030685","article-title":"A major outbreak of severe acute respiratory syndrome in Hong Kong","volume":"348","author":"N Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"pone.0248058.ref014","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"W Li","year":"2003","journal-title":"Nature"},{"key":"pone.0248058.ref015","doi-asserted-by":"crossref","first-page":"m810","DOI":"10.1136\/bmj.m810","article-title":"Preventing a covid-19 pandemic","volume":"368","author":"J Watkins","year":"2020","journal-title":"BMJ"},{"key":"pone.0248058.ref016","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40264-020-00935-2","article-title":"Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?","volume":"43","author":"G Trifiro","year":"2020","journal-title":"Drug Saf"},{"key":"pone.0248058.ref017","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"L Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"pone.0248058.ref018","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"17","author":"YY Zheng","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"pone.0248058.ref019","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism","volume":"383","author":"GI Rice","year":"2004","journal-title":"Biochem J"},{"key":"pone.0248058.ref020","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"CM Ferrario","year":"2005","journal-title":"Circulation"},{"key":"pone.0248058.ref021","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"K Kuba","year":"2005","journal-title":"Nat Med"},{"key":"pone.0248058.ref022","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","article-title":"Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study","volume":"76","author":"G Yang","year":"2020","journal-title":"Hypertension"},{"key":"pone.0248058.ref023","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","article-title":"Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)","volume":"5","author":"N Mehta","year":"2020","journal-title":"JAMA Cardiol"},{"key":"pone.0248058.ref024","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","article-title":"Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors","volume":"43","author":"Y Ishiyama","year":"2004","journal-title":"Hypertension"},{"key":"pone.0248058.ref025","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"124","author":"SC Smith","year":"2011","journal-title":"Circulation"},{"key":"pone.0248058.ref026","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"B Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"pone.0248058.ref027","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"C Huang","year":"2020","journal-title":"Lancet"},{"key":"pone.0248058.ref028","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)","volume":"5","author":"T Guo","year":"2020","journal-title":"JAMA Cardiol"},{"key":"pone.0248058.ref029","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00726-014-1889-6","article-title":"Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors","volume":"47","author":"RN Vuille-dit-Bille","year":"2015","journal-title":"Amino Acids"},{"key":"pone.0248058.ref030","article-title":"Angiotensin-converting enzyme inhibitor\/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease","author":"S Lebek","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"pone.0248058.ref031","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40885-018-0098-0","article-title":"Korea hypertension fact sheet 2018","volume":"24","author":"Korean Society Hypertension, Hypertension Epidemiology Research Working Group","year":"2018","journal-title":"Clin Hypertens"},{"key":"pone.0248058.ref032","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fmed.2020.00453","article-title":"Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19","volume":"7","author":"FA Cadegiani","year":"2020","journal-title":"Front Med (Lausanne)"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T18:43:42Z","timestamp":1615488222000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248058"}},"subtitle":[],"editor":[{"given":"Yoshihiro","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0248058","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]}}}